Status:
COMPLETED
Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate
Lead Sponsor:
Kaiser Permanente
Conditions:
Contrast Induced Nephropathy
Kidney Diseases
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Contrast nephropathy (CN) is a common cause of renal failure associated with prolonged hospitalization, significant morbidity/mortality, and cost. In addition, these patients may require temporary or ...
Eligibility Criteria
Inclusion
- GFR \< 60 mL/min/1.73m2. GFR will be adjusted by a correction factor as reported by our laboratory for patients self identifying as black.
- \> 18 years and have at least one of the following risk factors for contrast nephropathy: diabetes (type 2), congestive heart failure, hypertension (\> 140/90), or age \> 75.
- Both inpatients and outpatients will be offered enrollment.
Exclusion
- Patients unable to give consent
- Already receiving sodium bicarbonate solution
- Undergoing emergency cardiac catheterization
- Receiving a contrast agent other than Oxilan
- On hemodialysis
- Recent exposure to contrast within 2 days
- Pulmonary edema
- Active congestive heart failure
- Severe valvular abnormality
- Recent significant change in kidney function (\> 15% over 2d)
- One kidney
- Kidney transplant status
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00312117
Start Date
January 1 2006
End Date
February 1 2006
Last Update
March 11 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaiser Permanente Medical Center
Los Angeles, California, United States, 90027